Talent

Medical Devices

Stryker names Spencer Stiles CEO as Kevin Lobo moves to Executive Chair

Stryker's 27-year veteran Spencer Stiles will become CEO on 1 January 2027, as Kevin Lobo transitions to Executive Chair after tripling annual revenues.
Stryker's 27-year veteran Spencer Stiles will become CEO on 1 January 2027, as Kevin Lobo transitions to Executive Chair after tripling annual revenues.
The Biotech Times Editorial Team  · 
Cell & Gene Therapy

Ernexa Therapeutics names Spiegel to board ahead of ERNA-101 IND

Ernexa Therapeutics has appointed oncology veteran Robert Spiegel to its board as it targets a Q4 2026 IND filing for its lead iMSC cell therapy.
Ernexa Therapeutics has appointed oncology veteran Robert Spiegel to its board as it targets a Q4 2026 IND filing for its lead iMSC cell therapy.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Medical Devices
Regulatory Science

Crossject expands board and hires ex-FDA lead ahead of ZEPIZURE launch

The French specialty pharma firm has added three executives to its board and appointed a former FDA reviewer to lead US regulatory strategy for ZEPIZURE.
The French specialty pharma firm has added three executives to its board and appointed a former FDA reviewer to lead US regulatory strategy for ZEPIZURE.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Regulatory Science

HMNC Brain Health names Doebler CEO ahead of Phase 3 push

The Munich neuroscience company promotes its Chief Business Officer to lead Ketabon and Nelivabon into late-stage development following a $50m Series B close.
The Munich neuroscience company promotes its Chief Business Officer to lead Ketabon and Nelivabon into late-stage development following a $50m Series B close.
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

Bavarian Nordic appoints Tarja Stenvall as CEO from October

The Danish vaccine company has named Sanofi and AstraZeneca veteran Tarja Stenvall as its new chief executive, effective 15 October 2026.
The Danish vaccine company has named Sanofi and AstraZeneca veteran Tarja Stenvall as its new chief executive, effective 15 October 2026.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Giovanni Caforio joins CD&R as Operating Advisor for healthcare

The former Bristol Myers Squibb CEO brings 35 years of biopharma experience to CD&R's healthcare investment and portfolio strategy.
The former Bristol Myers Squibb CEO brings 35 years of biopharma experience to CD&R's healthcare investment and portfolio strategy.
The Biotech Times Editorial Team  · 
Biotech

SGU and Taaleem open medical school pathways for UAE students

St. George's University and UAE school group Taaleem have signed an MoU giving eligible students access to MD admissions pathways and up to USD
St. George's University and UAE school group Taaleem have signed an MoU giving eligible students access to MD admissions pathways and up to USD
The Biotech Times Editorial Team  · 
Diagnostics
Regulatory Science

Envetec appoints Thermo Fisher diagnostics chief to board

Envetec has named Patrick S. Jones, president of Thermo Fisher's Clinical Diagnostics Division, as an independent director to support its US expansion.
Envetec has named Patrick S. Jones, president of Thermo Fisher's Clinical Diagnostics Division, as an independent director to support its US expansion.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Tangram Therapeutics advances TGM-312 into MASH patient cohorts

The London RNAi biotech said its siRNA candidate cleared a safety review in healthy volunteers and now enters multiple ascending dose testing in MASH patients.
The London RNAi biotech said its siRNA candidate cleared a safety review in healthy volunteers and now enters multiple ascending dose testing in MASH patients.
The Biotech Times Editorial Team  · 
Biologics
Regulatory Science

Vaxcyte hires CMO and CLO as VAX-31 readout moves to October

Vaxcyte has appointed two senior executives and narrowed its OPUS-1 Phase 3 topline data window to end of October 2026.
Vaxcyte has appointed two senior executives and narrowed its OPUS-1 Phase 3 topline data window to end of October 2026.
The Biotech Times Editorial Team  · 
Regulatory Science

Inventiva appoints Chris Benecchi as COO ahead of MASH Phase 3 readout

The French-American biotech has hired a 30-year industry veteran to lead operational and commercial readiness as its lanifibranor Phase 3 data approaches.
The French-American biotech has hired a 30-year industry veteran to lead operational and commercial readiness as its lanifibranor Phase 3 data approaches.
The Biotech Times Editorial Team  · 
Biologics

Coloplast reshuffles ELT with new CPO and Wound unit interim lead

Coloplast appoints Amanda Rajkumar as Chief People Officer and moves Kerecis founder Fertram Sigurjonsson into an innovation advisory role.
Coloplast appoints Amanda Rajkumar as Chief People Officer and moves Kerecis founder Fertram Sigurjonsson into an innovation advisory role.
The Biotech Times Editorial Team  · 
Digital Health

Vituity CEO says hiring alone won't fix physician burnout crisis

Imamu Tomlinson, CEO of the $2.6bn physician-owned partnership, argues burnout is a systemic failure, not an individual one.
Imamu Tomlinson, CEO of the $2.6bn physician-owned partnership, argues burnout is a systemic failure, not an individual one.
The Biotech Times Editorial Team  · 

AlFaris International Appoints Nicholas Bingham as Strategic Advisor

AlFaris International Group has appointed Taranis Capital Founder and CEO Nicholas S. Bingham as Strategic Advisor to support its growth strategy.

AlFaris International Group has announced the appointment of Nicholas S. Bingham, Founder and Chief Executive Officer of Taranis Capital, as a Strategic Advisor to the Group. 

AlFaris International Appoints Nicholas Bingham as Strategic Advisor  · 
Digital Health

Ceribell adds two directors with device and health-system backgrounds

Nasdaq-listed Ceribell has appointed Thomas West and Sharon O'Keefe to its board as the point-of-care EEG platform reaches more than 680
Nasdaq-listed Ceribell has appointed Thomas West and Sharon O'Keefe to its board as the point-of-care EEG platform reaches more than 680
The Biotech Times Editorial Team  · 
Biologics

Anaveon promotes Laetitia Pouzol to Chief Scientific Officer

The Basel biotech has elevated its Head of Immunology to CSO, as ANV200 advances through IND-enabling studies toward clinical testing.
The Basel biotech has elevated its Head of Immunology to CSO, as ANV200 advances through IND-enabling studies toward clinical testing.
The Biotech Times Editorial Team  · 
Diagnostics

IBA reshuffles leadership as de Romrée takes operational control

IBA has elevated Henri de Romrée to full operational leadership while founder-era CEO Olivier Legrain shifts to board vice-chairman and strategic oversight.
IBA has elevated Henri de Romrée to full operational leadership while founder-era CEO Olivier Legrain shifts to board vice-chairman and strategic oversight.
The Biotech Times Editorial Team  · 
Biologics

Essential Pharma names Becki Morison as CEO from July 2026

The Egham-based rare disease pharma company has appointed the former LEO Pharma and Eli Lilly executive to lead its next phase of commercial growth.
The Egham-based rare disease pharma company has appointed the former LEO Pharma and Eli Lilly executive to lead its next phase of commercial growth.
The Biotech Times Editorial Team  · 
Cell & Gene Therapy
Genomics

Sangamo hires Raymond James to explore strategic alternatives

The genomic medicine company is weighing a sale or partnership as it advances a BLA-ready Fabry gene therapy and two CNS programmes.
The genomic medicine company is weighing a sale or partnership as it advances a BLA-ready Fabry gene therapy and two CNS programmes.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Regulatory Science

Santhera proposes Dr Srishti Gupta for board ahead of May AGM

The Swiss rare-disease pharma is putting the former Idorsia CEO forward as an independent director at its 26 May annual general meeting.
The Swiss rare-disease pharma is putting the former Idorsia CEO forward as an independent director at its 26 May annual general meeting.
The Biotech Times Editorial Team  · 
Subscribe to Talent